Three Unique CME Events Focusing on Gynecologic Cancers


March 16 – 18, 2019, Honolulu, Hawaii

Three Unique CME Events Focusing on Gynecologic Cancers

Please note that slides are for review only and not to be repurposed or published.

Data + Perspectives: Clinical Investigators Explore Emerging Research and Actual Patients with Uterine Sarcomas

Introduction:
Dr Love

MODULE 1: Clinical Decision-Making for Patients with Localized Uterine Leiomyosarcoma (uLMS)

Presentation — Dr Fader

Cases — Dr Leitao

MODULE 2: Sequence and Selection of Currently Available Therapeutic Options for Metastatic uLMS; Future Directions

Presentation — Dr Van Tine

Cases— Dr Secord

Live Poll Results
Download

Addressing Current Questions and Emerging Considerations with the Use of PARP Inhibitors in the Management of Ovarian Cancer

Introduction:
Dr Love

MODULE 1:
Genomic Testing and Management of Primary Ovarian Cancer — Dr Moore

MODULE 2:
Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer — Prof Ledermann

MODULE 3:
Prevention, Recognition and Management of PARP Inhibitor-Associated Side Effects — Dr Coleman

MODULE 4:
Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development — Dr Lheureux

Live Poll Results
Download

Novel Agents and Emerging Strategies in the Management of Gynecologic Cancers

Introduction:
Dr Love

MODULE 1:
Biologic Rationale for and Current Research Database with Immune Checkpoint Inhibition in Gynecologic Cancers — Dr Powell

MODULE 2:
Targeting Folate Receptor Alpha (FRα) in Patients with Gynecologic Cancers — Dr Birrer

MODULE 3:
Other Novel Agents and Strategies Under Investigation for CC, EC and OC — Dr O’Malley

MODULE 4:
Ongoing Trials Examining the Role of Anti-PD-1/PD-L1 Antibodies in Combination with Chemotherapy, Targeted Agents or Other Immunotherapeutics — Dr Westin

Live Poll Results
Download